Scholarlink

<p>Renal Cell Carcinoma (RCC) may uncommonly present concurrently with anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV). Most instances are malignancies discovered incidentally during the work up after a diagnosis of AAV; however, the significant overlap between these disorders potentially suggests a more complex pathophysiology. We present the case of a 53-year-old gentleman who was diagnosed with metastatic RCC who later developed rapidly progressive kidney failure and a vasculitic rash after commencement of a tyrosine kinase inhibitor and was ultimately diagnosed with subsequent concurrent AAV. Treatment included suspending immunotherapy, glucocorticoids, and rituximab induction. This case highlights the unique scenario of concurrent RCC and AAV, including the potential pathophysiology of a pro-inflammatory milieu created in the setting of RCC which permits AAV. It also outlines the complexity of treating an autoimmune disorder in the setting of an active cancer requiring immunotherapy and the difficult balance between these two treatment paradigms.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A case report of metastatic renal cell carcinoma and ANCA associated vasculitis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月3日

查看全文
  • Maddison Taylor,
  • Cassandra Rawlings,
  • George Kan,
  • Andrew J. Mallett,
  • Michelle Harfield

摘要

Renal Cell Carcinoma (RCC) may uncommonly present concurrently with anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV). Most instances are malignancies discovered incidentally during the work up after a diagnosis of AAV; however, the significant overlap between these disorders potentially suggests a more complex pathophysiology. We present the case of a 53-year-old gentleman who was diagnosed with metastatic RCC who later developed rapidly progressive kidney failure and a vasculitic rash after commencement of a tyrosine kinase inhibitor and was ultimately diagnosed with subsequent concurrent AAV. Treatment included suspending immunotherapy, glucocorticoids, and rituximab induction. This case highlights the unique scenario of concurrent RCC and AAV, including the potential pathophysiology of a pro-inflammatory milieu created in the setting of RCC which permits AAV. It also outlines the complexity of treating an autoimmune disorder in the setting of an active cancer requiring immunotherapy and the difficult balance between these two treatment paradigms.